Dr. Julie Goodman presents as a concerning intelligence gap for plaintiff attorneys, with minimal public record despite appearing as a defense expert in the high-stakes Camp Lejeune Water Litigation. Her credentials, institutional affiliation, and specific area of expertise remain undisclosed in available records, creating significant uncertainty about her qualifications and methodology. This lack of transparency is particularly notable given her involvement in Camp Lejeune cases, which typically involve complex environmental toxicology and epidemiological analysis requiring substantial specialized expertise. Her track record shows exclusive defense-side work, appearing three times for the United States in the Camp Lejeune litigation in April 2023. The absence of any Daubert challenges suggests either that her testimony has not yet been scrutinized or that cases settled before evidentiary hearings. This clean procedural record should not be mistaken for validation of her methodology or opinions, particularly given the incomplete credential profile. Plaintiff attorneys should treat Dr. Goodman as a high-risk unknown. The lack of available background information presents both a vulnerability and an opportunity—while her actual expertise remains unclear, this opacity creates strong grounds for aggressive Daubert challenges focusing on qualification thresholds, methodology disclosure, and reliability standards. Her exclusive defense orientation in environmental contamination cases suggests she will likely present opinions minimizing causation or exposure risks. Thorough pre-deposition investigation into her actual credentials, publication record, and methodology will be essential, as the current intelligence gap may mask either a formidable expert or someone whose qualifications cannot withstand scrutiny.
No Daubert challenges on record.
Free during beta. Your inquiry will be sent to MTAA and the expert if they've claimed their profile.
We'll send a verification link to your email. Once verified you can add contact info, bio, and availability.